The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 18, 2016
Filed:
Jan. 06, 2014
Applicant:
Clsn Laboratories, Inc., Wilmington, DE (US);
Inventors:
Jason G. Fewell, Madison, AL (US);
Majed Matar, Madison, AL (US);
Jennifer Rice, Grant, AL (US);
Danny H. Lewis, Hartselle, AL (US);
Khursheed Anwer, Madison, AL (US);
Assignee:
CLSN LABORATORIES, INC., Wilmington, DE (US);
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C12N 15/00 (2006.01); C12N 15/82 (2006.01); A61K 47/34 (2006.01); A61K 9/00 (2006.01); A61K 31/28 (2006.01); A61K 31/337 (2006.01); A61K 31/4745 (2006.01); A61K 31/704 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01); A61K 33/24 (2006.01); A61K 47/10 (2006.01); A61K 47/48 (2006.01); B82Y 5/00 (2011.01); C12N 15/87 (2006.01); A61K 31/17 (2006.01); A61K 31/664 (2006.01); A61K 31/7068 (2006.01); A61K 38/20 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
A61K 47/34 (2013.01); A61K 9/0019 (2013.01); A61K 9/0085 (2013.01); A61K 31/17 (2013.01); A61K 31/28 (2013.01); A61K 31/337 (2013.01); A61K 31/4745 (2013.01); A61K 31/664 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01); A61K 33/24 (2013.01); A61K 38/208 (2013.01); A61K 39/39558 (2013.01); A61K 47/10 (2013.01); A61K 47/48969 (2013.01); A61K 48/005 (2013.01); A61K 48/0041 (2013.01); B82Y 5/00 (2013.01); C12N 15/87 (2013.01);
Abstract
Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.